Institutional members access full text with Ovid®

Share this article on:

Use of Ceftaroline in Complicated Methicillin-Resistant Staphylococcus aureus Bacteremia

Zainah, Hadeel MD; Vazquez, Jose A. MD

Infectious Diseases in Clinical Practice: January 2013 - Volume 21 - Issue 1 - p 58–60
doi: 10.1097/IPC.0b013e3182602205
Case Reports

Ceftaroline is a novel broad-spectrum cephalosporin approved in October 2010 by the Food and Drug Administration for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by different organisms, including methicillin-resistant Staphylococcus aureus. We report 2 cases where ceftaroline was used effectively to treat complicated methicillin-resistant S aureus bacteremia.

From the Henry Ford Hospital, Detroit, MI.

Correspondence to: Jose A. Vazquez, MD, Henry Ford Hospital, 2799 W Grand Blvd, CFP 202, Detroit, MI 48202. E-mail:

J Vazquez is with the speakers’ bureaus of Pfizer, Astellas, Forest, and Merck. He has received grants from Merck and Astellas. H Zainah has no funding or conflicts of interest to disclose.

The authors have no funding to disclose.

© 2013 Lippincott Williams & Wilkins, Inc.